Turn Therapeutics Adjusts Eczema Trial Design Following Promising Interim Results

Turn Therapeutics has modified the second stage of its GX-03 Phase II trial for eczema, based on positive interim patient data. The initial findings indicated stronger responses in patients with specific itch scores and lower EASI scores. The company aims to optimize the trial population for better efficacy, while the drug has maintained a favorable safety profile.